BioPharma Resources

Drug Trial Radar · NCT03400878

Comparing Morbidity and Mortality Effects of Two Different Strains of BCG

Evaluating the Non-specific Effects of Different BCG Strains in Guinea-Bissau: Randomized Trial of the Impact on Early-life Hospital Admissions and Deaths

Last checked: Nov 19, 2026Latest source record: Dec 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 17,505 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

17,505

Actual

Start

Oct 14, 2017

Primary completion

Jun 1, 2020

Study completion Oct 1, 2020

Sponsor

Lead sponsor
Bandim Health ProjectAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Research Center for Vitamins and Vaccines
First posted
Jan 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (care provider, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, up to 42 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Background: Investigators at Bandim Health Project (BHP, www.bandim.org) in Guinea-Bissau have shown in several randomized trials that the Bacille-Calmette-Guérin (BCG) vaccine against tuberculosis (TB) is associated with reduced mortality in the first months of life. BCG is a live attenuated vaccine, which means that it consists of active tuberculosis bacteria that are not capable of infecting a human with TB. BCG has been grown and maintained at many different laboratories all over the world using slightly different laboratory techniques. Due to the accumulation of genetic mutations in the different BCG strains, many variants of the vaccine exists today. These have different properties when it comes to immune response, side effects, protection against TB and scar formation. The BCG scar status after vaccination is a good marker for the non-specific effects of the vaccine; among BCG-vaccinated infants, those with a BCG scar have improved survival. The investigators hypothesize that the different types of BCG vary in terms of the strength of the non-specific effects and thus the impact on overall morbidity and mortality. In the trial, the investigators will compare the two most widely used BCG strains in the world, BCG-Russia and BCG-Japan, with respect to their non-specific effects on morbidity and mortality. As an addition, the investigators will study the effect of maternal BCG vaccination on the subsequent effect of BCG-vaccination in the offspring, since there are indications that the maternal BCG scar status primes for a stronger non-specific response in the offspring.

Conditions

  • Heterologous Immunity
  • Infant Morbidity
  • Infant Mortality
  • Trained Immunity
  • Vaccine Reaction
  • Vaccine Adverse Reaction

Interventions

  • BCG-JapanBiological

    One dose of 0.05 ml BCG-Japan vaccine applied to the left deltoid region.

  • BCG-RussiaBiological

    One dose of 0.05 ml BCG-Russia vaccine applied to the left deltoid region.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hospital admission at National Hospital Simão Mendes Pediatric WardTime frame: 6 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Bandim Health Project, Apartado 861

    Bissau, Guinea-Bissau

  • Bandim Health Project

    Bissau, Guinea-Bissau

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.